<?xml version="1.0"?>
<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
         xmlns:dc="http://purl.org/dc/elements/1.1/"
         xmlns:syn="http://purl.org/rss/1.0/modules/syndication/"
         xmlns="http://purl.org/rss/1.0/">




    



<channel rdf:about="http://www.unchealthcare.org/news/latestnews/RSS">
  <title>Latest news from UNC Health Care</title>
  <link>http://www.unchealthcare.org</link>
  
  <description>
    
       This is an RSS (Really Simple Syndication) feed of the latest news items from UNC Health Care and the UNC Chapel Hill School of Medicine. You'll need to download and install one of the free RSS readers that are available -- such as Google Reader -- in order to start receiving this feed. Once your reader is installed, you can click on the RSS icon above to add this feed. Or, you could paste this link into your reader: http://www.unchealthcare.org/news/latestnews/RSS. Either way should work.
       
  </description>

  
  
            <syn:updatePeriod>hourly</syn:updatePeriod>
            <syn:updateFrequency>1</syn:updateFrequency>
            <syn:updateBase>2008-09-24T21:13:51Z</syn:updateBase>
        
  
  <image rdf:resource="http://www.unchealthcare.org/somLogo.gif"/>

  <items>
    <rdf:Seq>
        
            <rdf:li rdf:resource="http://www.unchealthcare.org/site/newsroom/news/2009/November/erickstory"/>
        
        
            <rdf:li rdf:resource="http://www.unchealthcare.org/site/newsroom/news/2009/November/thanksgiving"/>
        
        
            <rdf:li rdf:resource="http://www.unchealthcare.org/site/newsroom/news/2009/November/flibanserin"/>
        
        
            <rdf:li rdf:resource="http://www.unchealthcare.org/site/newsroom/news/2009/November/exit"/>
        
        
            <rdf:li rdf:resource="http://www.unchealthcare.org/site/newsroom/news/2009/November/bestdocs09"/>
        
        
            <rdf:li rdf:resource="http://www.unchealthcare.org/site/newsroom/news/2009/November/mcallister"/>
        
        
            <rdf:li rdf:resource="http://www.unchealthcare.org/site/newsroom/news/2009/November/roth"/>
        
        
            <rdf:li rdf:resource="http://www.unchealthcare.org/site/newsroom/news/2009/October/itouch"/>
        
        
            <rdf:li rdf:resource="http://www.unchealthcare.org/site/newsroom/news/2009/October/bcrf"/>
        
        
            <rdf:li rdf:resource="http://www.unchealthcare.org/site/newsroom/news/2009/October/goldberg"/>
        
        
            <rdf:li rdf:resource="http://www.unchealthcare.org/site/newsroom/news/2009/October/dominski"/>
        
        
            <rdf:li rdf:resource="http://www.unchealthcare.org/site/newsroom/news/2009/October/fhd6"/>
        
    </rdf:Seq>
  </items>

</channel>


    <item rdf:about="http://www.unchealthcare.org/site/newsroom/news/2009/November/erickstory">
    <title>A Blessing to Many: Erick's Story</title>
    <link>http://www.unchealthcare.org/site/newsroom/news/2009/November/erickstory</link>
    <description>Erick Gomez-Fuentes was born with "Prune Belly Syndrome," a defect that occurs once in every 40,000 births. This video tells his story.</description>   
    <content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<object width="560" align="center" height="340"><embed src="http://www.youtube.com/v/a-PzC2eU2qg&amp;hl=en_US&amp;fs=1&amp;" type="application/x-shockwave-flash" allowscriptaccess="always" allowfullscreen="true" width="560" height="340"></object> <p></p> <p><span>Erick Gomez-Fuentes was born with &quot;Prune Belly Syndrome,&quot; a defect that occurs once in every 40,000 births. Erick has been at UNC Hospitals since his birth in 2008 and has already touched the hearts of the doctors and nurses on his floor. His family's love and determination has sustained Erick as he awaits an intestinal transplant. Though the obstacles to Erick living a normal life are huge, his mother is determined to help him get well. </span></p>]]></content:encoded>
        <dc:publisher>No publisher</dc:publisher>
        <dc:creator>tom_hughes</dc:creator>
        <dc:rights></dc:rights>
        <dc:date>2009-11-19T15:25:19Z</dc:date>
        <dc:type>News Item</dc:type>
        </item>

    <item rdf:about="http://www.unchealthcare.org/site/newsroom/news/2009/November/thanksgiving">
    <title>Don’t add an ER visit to your holiday plans</title>
    <link>http://www.unchealthcare.org/site/newsroom/news/2009/November/thanksgiving</link>
    <description>UNC emergency physician Abhi Mehrotra, M.D., explains how you can avoid the most common injuries that land people in a hospital emergency department during the four-day Thanksgiving holiday period. </description>   
    <content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<p><span style="font-weight: bold;">Media contact:</span> Tom Hughes, (919) 966-6047,<a href="mailto:tahughes@unch.unc.edu"> tahughes@unch.unc.edu </a><br /><br />Wednesday, Nov. 18, 2009<span style="font-style: italic;"><br /><br />Written by Margot Carmichael Lester for UNC Health Care</span><br /><br />Visiting is a big part of the Thanksgiving holiday. But one place you don&rsquo;t want to stop by is the Emergency Department. <br /><br />&ldquo;Most people who come in over that four-day period are here for fever, back pain, abdominal pain and chest pain,&rdquo; explains <a href="http://findadoc.unchealthcare.org/directory/profile.asp?dbase=main&amp;setsize=10&amp;last=mehrotra&amp;pict_id=0002121" target="_blank">Abhi Mehrotra, M.D.</a>, assistant medical director in the <a href="http://www.med.unc.edu/emergmed" target="_blank">Department of Emergency Medicine</a> at the <a href="http://www.med.unc.edu">University of North Carolina at Chapel Hill School of Medicine</a>. &ldquo;That&rsquo;s not unexpected because those are the most common complaints anyway.&rdquo; <br /><br />But there are those of us who need medical attention for lacerations, burns and other injuries that stem directly from holiday-related activities. <br /><br /><span style="font-weight: bold;">Lacerations</span><br />At Thanksgiving, it&rsquo;s not unusual to have too many cooks in the kitchen. Needless to say, keep knives and other sharp objects out of reach of children &ndash; and anyone else who&rsquo;s likely to be a little too cavalier about carving. <br /><br />&ldquo;Pay attention to what you&rsquo;re doing and be vigilant about where things are &ndash; that&rsquo;s best way to avoid injury,&rdquo; Mehrotra says. &ldquo;Make sure you&rsquo;re familiar with the equipment before you start using it. And don&rsquo;t rush.&rdquo;<br /><br /><span style="font-weight: bold;">Burns</span><br />Many of us like to try something new for the big meal. Deep-fried turkey is a popular &ndash; and potentially dangerous &ndash; way to prepare the bird. Just remember that you want people oohing and ahhing over the finished product, not the preparatory pyrotechnics.<br /><br />&ldquo;The bird should be fresh or thawed &ndash; not frozen &ndash; and be careful to raise and lower it slowly to avoid splashing the hot grease,&rdquo; Mehrotra explains. &ldquo;It&rsquo;s also important to make sure you don&rsquo;t have any skin exposed. Wear a long-sleeved shirt and gloves for protection. Finally, have a working fire extinguisher nearby at all times.&rdquo;&nbsp; <br /><br /><span style="font-weight: bold;">Dietary Issues</span><br />Thanksgiving is the biggest eating day of the year, and even the most vigilant of us can easily overindulge. <br /><br />&ldquo;The data shows large meals are less healthy than smaller meals more frequently,&rdquo; Mehrotra says. &ldquo;So if you want to have the same amount of turkey, spread it out over several hours. You&rsquo;ll feel better for it.&rdquo; You can still take a nap during the third quarter of the football game, though.<br /><br />And don&rsquo;t forget that dietary restrictions still apply even on holidays. If you&rsquo;re on a special diet for health reasons, do your best to stick to it. If you just can&rsquo;t resist Aunt Beulah&rsquo;s super-sweet pumpkin pie cheesecake or Uncle Zeb&rsquo;s salty country ham, take a tiny portion to savor. <br /><br /><span style="font-weight: bold;">Overexertion</span><br />Shopping on Thanksgiving weekend is like a full-contact marathon. Between the rock-bottom, door-buster deals offered on Black Friday and Cyber Monday, it&rsquo;s possible to damage more than your bank balance. <br /><br />If you&rsquo;re hitting the stores, avoid overexerting yourself. Even if you&rsquo;re going with Cousin Sue, the super-shopper, remember that &ldquo;shop till ya drop&rdquo; is just an expression, not a command. &ldquo;It&rsquo;s important to pace yourself,&rdquo; Mehrotra says. This is especially wise if you&rsquo;re unaccustomed to being on your feet for long periods, or if you don&rsquo;t get much regular exercise. &ldquo;Plan breaks where you can sit down and rest a little. And make sure you keep hydrated throughout the day.&rdquo; Think of all the great people-watching you can do during that break.<br /><br />You&rsquo;re not out of the woods just because you do your shopping on Cyber Monday. If you&rsquo;re not careful, you could find muscle pain, stiffness and eye strain in your online shopping cart. &ldquo;You want to have adequate lighting and your computer and chair positioned well for back, eyes and arms,&rdquo; Mehrotra notes. Step away from the computer periodically to give your upper body a break.&nbsp; <br /><br />&ldquo;Moderation, prevention and good old common sense are the best ways to avoid an emergency room visit,&rdquo; Mehrotra says. &ldquo;But if you&rsquo;re not feeling well, come in.&nbsp; The nurses, physicians, and staff of the Emergency Department are here to care for you 24/7, including the holidays.&rdquo;</p>]]></content:encoded>
        <dc:publisher>No publisher</dc:publisher>
        <dc:creator>tom_hughes</dc:creator>
        <dc:rights></dc:rights>
        <dc:date>2009-11-18T19:09:28Z</dc:date>
        <dc:type>News Item</dc:type>
        </item>

    <item rdf:about="http://www.unchealthcare.org/site/newsroom/news/2009/November/flibanserin">
    <title>Viagra for women? Drug developed as antidepressant effective in treating low libido</title>
    <link>http://www.unchealthcare.org/site/newsroom/news/2009/November/flibanserin</link>
    <description>Pooled results from three separate clinical trials of flibanserin, a drug originally created as an antidepressant, show it is effective in treating women with acquired hypoactive sexual desire disorder. These trials were the first ever to test a therapy that works at the level of the brain to enhance libido in women reporting low sexual desire. </description>   
    <content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<p><span style="font-weight: bold;">Media contact:</span> Tom Hughes, (919) 966-6047, <a href="mailto:tahughes@unch.unc.edu">tahughes@unch.unc.edu </a><br /><br />Monday, Nov. 16, 2009<br /><br />CHAPEL HILL &ndash; The drug flibanserin, which was originally created as an antidepressant, is effective in treating women with low libido, pooled results from three separate clinical trials have found.<br /><br />These trials were the first ever to test a therapy that works at the level of the brain to enhance libido in women reporting low sexual desire, said <a target="_blank" href="http://findadoc.unchealthcare.org/directory/profile.asp?dbase=main&amp;setsize=10&amp;last=thorp&amp;pict_id=0000671">John M. Thorp Jr., M.D.</a>, McAllister distinguished professor of obstetrics and gynecology at the <a target="_blank" href="http://med.unc.edu">University of North Carolina at Chapel Hill School of Medicine</a> and the principal investigator for North America in the studies.<br /><br />&ldquo;Flibanserin was a poor antidepressant,&rdquo; Thorp said. &ldquo;However, astute observers noted that it increased libido in laboratory animals and human subjects. So, we conducted multiple clinical trials and the women in our studies who took it for hypoactive sexual desire disorder reported significant improvements in sexual desire and satisfactory sexual experiences.<br /><br />&ldquo;It&rsquo;s essentially a Viagra-like drug for women in that diminished desire or libido is the most common feminine sexual problem, like erectile dysfunction is in men,&rdquo; Thorp said. <br /><br />Studies have shown that the prevalence of hypoactive sexual desire disorder in the U.S. ranges from 9 percent to 26 percent of women, depending on age and menopausal status. Flibanserin is currently an investigational drug and is available only to women taking part in clinical trials.<br /><br />The results reported here were presented Monday, Nov. 16, at the <a target="_blank" href="http://www.essm-congress.org/">Congress of the European Society for Sexual Medicine</a> in Lyon, France. The presentation was given by Elaine E. Jolly, M.D., overall principal investigator and a professor at the University of Ottawa in Canada.<br />&nbsp;<br />Jolly, Thorp and colleagues pooled data from four clinical trials of flibanserin conducted in the U.S., Canada and Europe. A total of 1,946 pre-menopausal women ages 18 and older were randomized to receive either flibanserin or placebo for 24 weeks, with 4 weeks of pre-treatment baseline measurement and 4 weeks of post-treatment follow-up. <br /><br />Initially, four different dosing regimens were used in the trials: 25 milligrams twice a day, 50 milligrams once a day at bedtime, 50 milligrams twice a day and 100 milligrams once a day at bedtime. The dosing regimens totaling 50 milligrams a day were not effective while the regimens totaling 100 milligrams were.&nbsp; So, the results being reported are from only three of the four trials and are based on the 100 milligrams once a day dosing regimen only.<br /><br />The trials measured mean changes from baseline on the following six variables as reported by the women each week: number of satisfying sexual events (SSE), electronic diary (eDiary) desire score, female sexual function index (FSFI) desire domain score, FSFI total score, female sexual distress scale-revised (FSDR-R), and FSDR-R Item 13 (which focuses specifically on desire/libido). <br /><br />The researchers concluded that treatment with 100 milligrams of flibanserin once a day was associated with significant improvements versus placebo in the number of satisfying sexual events (SSE) reported, sexual desire (as measured by eDiary and FSFI desire domain), a reduction in distress associated with sexual dysfunction (as measured by FSDS-R and its Item 13), and sexual functioning as measured by FSFI.<br /><br />&ldquo;These results point to a novel approach to pharmacologic treatment of the sexual problem that plagues reproductive age women the most, and may over time prove to be an effective treatment without the side effects of androgen replacement therapy, which is the only treatment currently available,&rdquo; Thorp said. <br /><br />The trials were funded by Boehringer Ingelheim Pharmaceuticals, the manufacturer of flibanserin.</p>]]></content:encoded>
        <dc:publisher>No publisher</dc:publisher>
        <dc:creator>tom_hughes</dc:creator>
        <dc:rights></dc:rights>
        <dc:date>2009-11-16T12:41:23Z</dc:date>
        <dc:type>News Item</dc:type>
        </item>

    <item rdf:about="http://www.unchealthcare.org/site/newsroom/news/2009/November/exit">
    <title>UNC maternal-fetal medicine leads team in EXIT delivery</title>
    <link>http://www.unchealthcare.org/site/newsroom/news/2009/November/exit</link>
    <description>A baby was delivered at UNC Hospitals on Thursday, Nov. 12, via an EXIT (ex utero intrapartum fetal treatment) procedure. A rare occurrence anywhere, it was the third EXIT procedure performed at UNC Hospitals since 2003. </description>   
    <content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<p><strong>Media contact:</strong> Clinton Colmenares, (919) 966-6047, <a href="mailto:ccolmena@unch.unc.edu">ccolmena@unch.unc.edu</a><br /><br />Friday, Nov. 13, 2009<br /><br />CHAPEL HILL -- For one baby delivered at UNC on Thursday (Nov. 12, 2009), its entrance into the world was made through an EXIT, an ex utero intrapartum fetal treatment procedure.</p><p>A rare occurrence anywhere, it was the third EXIT performed at UNC since <a target="_blank" href="http://findadoc.unchealthcare.org/directory/profile.asp?dbase=main&amp;setsize=10&amp;last=chescheir&amp;pict_id=7122308">Nancy Chescheir, M.D.,</a> performed the first in 2003. EXIT is a specialized fetal intervention procedure employed most commonly when problems during pregnancy may obstruct the fetus&rsquo;s airway. In such cases, if the baby were delivered without the intervention, it could&nbsp; be at risk for a loss of oxygen, says <a target="_blank" href="http://findadoc.unchealthcare.org/directory/profile.asp?dbase=main&amp;setsize=10&amp;last=goodnight&amp;pict_id=8458215">Bill Goodnight, M.D.,</a> assistant professor in the <a target="_blank" href="http://www.med.unc.edu/obgyn">Department of Obstetrics and Gynecology</a> who led a team of more than a dozen physicians and nurses in the procedure.</p><p>In EXIT, surgeons perform a specialized C-section while the mom is under general anesthesia in which&nbsp;the baby is partially delivered &ndash; head first, then a shoulder and an arm &ndash; leaving the baby attached to the placenta by the umbilical cord. The placenta continues to provide oxygen to the baby while the newborn&rsquo;s airway is established.</p><p>In the procedure Thursday, &ldquo;we had the baby on placental circulation for about 15 minutes,&rdquo; Goodnight says. The team completed intubation and confirmed the airway with endoscopy then finished delivering the baby with no complications. &ldquo;The baby went off to the nursery and the mom&rsquo;s doing well.&rdquo; The family chooses to remain anonymous.</p><p>At 28 weeks gestation a mass was detected on the baby&rsquo;s neck, and Drs. Goodnight and <a target="_blank" href="http://www.med.unc.edu/obgyn/departmental-divisions/maternal-fetal-medicine/personnel/Hickman">Ashley Hickman, M.D.,</a> a senior fellow in obstetrics and gynecology, started thinking about the need&nbsp; for delivery via EXIT. The mass continued to grow, and about a month ago a fetal MRI showed that the growth had begun to deviate the trachea, and was possibly affecting the fetus&rsquo;s ability to swallow, so Goodnight began planning the EXIT.</p><p>Goodnight and Hickman are part of the <a target="_blank" href="http://www.mombaby.org/">Center for Maternal &amp; Infant Health</a>, which meets weekly with colleagues from other disciplines to review and coordinate care for babies with anomalies.</p><p>&ldquo;Our goal is to provide all services available for the sickest babies in North Carolina. The collective expertise of this group allows us to do that, while coordinating care with a woman&rsquo;s local doctor,&rdquo; says Goodnight, who graduated from the UNC School of Medicine and completed a fellowship in maternal fetal medicine at the Medical University of South Carolina before returning to UNC last year.</p><p>&ldquo;At UNC, we take our mission to the people of North Carolina very seriously,&rdquo; says <a target="_blank" href="http://findadoc.unchealthcare.org/directory/profile.asp?dbase=main&amp;setsize=10&amp;pict_id=0003164">Daniel Clarke-Pearson, M.D.,</a> chairman of obstetrics and gynecology. &ldquo;We are fortunate to have a collection of extremely skilled and caring physicians, in our department and across the hospital, that enables us to meet our mission.&rdquo;</p><p>Kathleen Smith, M.D., and Adriene Ray, M.D., from <a target="_blank" href="http://www.med.unc.edu/anesthesiology">adult anesthesiology</a> had an especially crucial role, Goodnight says, because the mother had to be under general anesthesia while keeping the uterus relaxed and blood flow to the placenta normal.</p><p>Nate Nonoy, M.D., and Michael Danekas, M.D., from <a target="_blank" href="http://www.med.unc.edu/anesthesiology/our-department/clinical-divisions-sections/pediatric-division">pediatric anesthesiology</a> intubated the baby. Others on the team included George Retsch-Bogart, M.D., and Kathy Adobe from <a target="_blank" href="http://www.med.unc.edu/pediatrics/pediatric-specialties/pulmonology">pediatric pulmonology</a>; Cyril Engmann, M.D., and Lynne Harrington Johnson, M.D. from <a target="_blank" href="http://pediatrics.med.unc.edu/pediatric-specialties/neonatal-perinatal-medicine">neonatal-perinatal medicine</a>; and Amelia Drake in <a target="_blank" href="http://www.unc-ent.org/">otolaryngology.</a></p><p>Over the next few days doctors will carefully keep watch over the baby and determine the best way to remove the growth.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p>]]></content:encoded>
        <dc:publisher>No publisher</dc:publisher>
        <dc:creator>tom_hughes</dc:creator>
        <dc:rights></dc:rights>
        <dc:date>2009-11-13T20:28:11Z</dc:date>
        <dc:type>News Item</dc:type>
        </item>

    <item rdf:about="http://www.unchealthcare.org/site/newsroom/news/2009/November/bestdocs09">
    <title>219 UNC physicians listed in The Best Doctors in America  2009-2010</title>
    <link>http://www.unchealthcare.org/site/newsroom/news/2009/November/bestdocs09</link>
    <description>More than 200 University of North Carolina at Chapel Hill School of Medicine physicians are included in the latest compilation of The Best Doctors in America database.</description>   
    <content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<p><span style="font-weight: bold;"><br />Media contact: </span>Tom Hughes, (919) 966-6047, <a href="mailto:tahughes@unch.unc.edu">tahughes@unch.unc.edu </a><br /><br />Friday, Nov. 13, 2009<br /><br />CHAPEL HILL &ndash; More than 200 <a href="http://www.med.unc.edu">University of North Carolina at Chapel Hill School of Medicine</a> physicians are included in the latest compilation of <a href="http://www.bestdoctors.com/bd/" target="_blank">The Best Doctors in America&reg;</a> database.<br /><br />In addition, many of these doctors are also listed in the November 2009 issue of <a href="http://www.businessnc.com/index.php?src=" target="_blank">Business North Carolina</a> magazine, as part of its <a href="http://www.businessnc.com/index.php?src=gendocs&amp;ref=BestDocs2008&amp;category=BestDocs" target="_blank">annual compilation</a> of the best doctors in North Carolina.<br /><br />Only 3 to 5 percent of physicians in each country where Best Doctors is present are included in its database. The Best Doctors database contains the names and professional affiliations of approximately 45,000 doctors in the United States, all chosen through an exhaustive peer-review survey that asks: &ldquo;If you or a loved one needed a doctor in your specialty, to whom would you refer them?&rdquo; The peer review process as well as additional research conducted by Best Doctors determines selections for each list.<br /><br />The 219 UNC physicians, listed by their medical specialty (as the specialty is identified in the Best Doctors database), are:<br /><br /><span style="font-weight: bold;">Allergy and Immunology</span> - Nortin M. Hadler (also listed in Geriatric Medicine and Rheumatology), David B. Peden<br /><span style="font-weight: bold;">Anesthesiology</span> - David C. Mayer, Anthony N. Passannante, David A. Zvara<br /><span style="font-weight: bold;">Cardiovascular Disease</span> - Kirkwood Adams, John Paul Mounsey, Marschall S. Runge, Sidney C. Smith, Jr., David Tate, Park W. Willis IV<br /><span style="font-weight: bold;">Colon and Rectal Surgery</span> - Mark J. Koruda<br /><span style="font-weight: bold;">Critical Care Medicine</span> -- Philip Boysen, David C. Henke (also listed in Pulmonary Medicine), James R. Yankaskas (also listed in Pulmonary Medicine)<br /><span style="font-weight: bold;">Dermatology</span> - Sue Ellen Cox, Luis A. Diaz, Stanley B. Levy, David Scott Rubenstein, Nancy E. Thomas<br /><span style="font-weight: bold;">Endocrinology and Metabolism</span> - Susan Braithwaite, John B. Buse, David Clemmons, Jean Dostou, Thomas L. O&rsquo;Connell, David A. Ontjes, Janet E. Rubin, Julie L. Sharpless<br /><span style="font-weight: bold;">Family Medicine </span>- Evan A. Ashkin, Timothy P. Daaleman, Allen J. Daugird, Clark R. Denniston, Jeffrey Furman, G. Patrick Guiteras, Robert E. Gwyther, Andrew Hannapel, Margaret Helton, James P. Manor, Warren P. Newton, Susan F. Slatkoff, Donald Spencer, Beat D. Steiner, Adam Jason Zolotor<br /><span style="font-weight: bold;">Gastroenterology</span> - Douglas A. Drossman, Ian S. Grimm, Hans Herfarth, Kim L. Isaacs, Roy Charles Orlando, Robert Sandler, R. Balfour Sartor, Nicholas J. Shaheen<br /><span style="font-weight: bold;">Geriatric Medicine</span> &ndash; Jan Busby-Whitehead, M. Andrew Greganti, Nortin M. Hadler (also listed in Allergy and Immunology and Rheumatology), Laura C. Hanson, Philip D. Sloane<br /><span style="font-weight: bold;">Hand Surgery</span> - Donald K. Bynum, Jr.<br /><span style="font-weight: bold;">Hepatology</span> &ndash; Michael Warren Fried, Paul H. Hayashi, Steven Zacks<br /><span style="font-weight: bold;">Infectious Disease</span> - Myron Cohen, Joseph J. Eron, Jr., P. Frederick Sparling, Charles M. van der Horst <br /><span style="font-weight: bold;">Internal Medicine</span> - Marco A. Aleman, Timothy Carey, Paul R. Chelminski, Cristin M. Colford, John S. Kizer, James E. Kurz (also listed in Pediatrics), Michael Pignone, Amy W. Shaheen <br /><span style="font-weight: bold;">Medical Genetics</span> - James P. Evans, Joseph Muenzer (also listed in Pediatric Specialist)<br /><span style="font-weight: bold;">Medical Oncology and Hematology</span> - Stephan Alan Bernard, Lisa A. Carey, Elizabeth Claire Dees, Richard M. Goldberg, Nigel S. Key, Stephan Moll, W. Kimryn Rathmell, Thomas C. Shea, Mark Anthony Socinski <br /><span style="font-weight: bold;">Nephrology</span> - Randal K. Detwiler, Ronald J. Falk, Maria E. Ferris (also listed in Pediatric Specialist), Gerald A. Hladik, Patrick H. Nachman<br /><span style="font-weight: bold;">Neurological Surgery</span> - Matthew G. Ewend<br /><span style="font-weight: bold;">Neurology</span> &ndash; James F. Howard Jr., Peter Lars Jacobson (also listed in Pain Medicine), Daniel I. Kaufer, Caroline M. Klein, William J. Powers, Bradley Vaughn (also listed in Sleep Medicine)<br /><span style="font-weight: bold;">Nuclear Medicine</span> - William H. McCartney<br /><span style="font-weight: bold;">Obstetrics and Gynecology</span> - John F. Boggess, Kim Boggess, Wendy R. Brewster, Nancy C. Chescheir, Daniel L. Clarke-Pearson, Wesley C. Fowler, Jr., Marc A. Fritz, Paola Alvarez Gehrig, William H. Goodnight III, David A. Grimes, M. Kathryn Menard, John T. Soper, Robert Strauss, John M. Thorp Jr., Linda Van Le, Honor M. Wolfe <br /><span style="font-weight: bold;">Ophthalmology</span> - Kenneth L. Cohen, Jonathan J. Dutton, W. Craig Fowler, Mary Elizabeth Hartnett, Travis A. Meredith<br /><span style="font-weight: bold;">Orthopaedic Surgery</span> - Laurence E. Dahners, Douglas R. Dirschl, Shepard R. Hurwitz, Paul F. Lachiewicz, Timothy N. Taft<br /><span style="font-weight: bold;">Otolaryngology</span> - Craig Buchman, Harold C. Pillsbury III, Brent A. Senior, William W. Shockley, Mark C. Weissler, Carlton Zdanski<br /><span style="font-weight: bold;">Pain Medicine</span> &ndash; Peter Lars Jacobson (also listed in Neurology), J. Douglas Mann<br /><span style="font-weight: bold;">Pathology</span> - J. Charles Jennette<br /><span style="font-weight: bold;">Pediatric Specialist</span> &ndash; William T. Adamson, Joshua J. Alexander, Pierre Barker, L. Jarrett Barnhill (also listed in Psychiatry), Robert A. Bashford (also listed in Psychiatry), Thomas H. Belhorn, Julie Blatt, Carl Bose, Edmund R. Campion, A. Joseph D'Ercole, Stephanie D. Davis, Amelia F. Drake, Maria E. Ferris (also listed in Nephrology), Carol A. Ford, Debbie Sue Gipson, Stuart Gold, Robert S. Greenwood, Frederick W. Henderson, Marianna M. Henry, James J. Jenson, Margaret W. Leigh, Steven N. Lichtman, Steven N. Lichtman, Michael R. Mill (also listed in Thoracic Surgery), Joseph Muenzer (also listed in Medical Genetics), Marianne Muhlebach, Albert Jackson Naftel, Terry Lee Noah, J. Duncan Phillips, Joseph Piven (also listed in Psychiatry), Elisabeth S. Potts Dellon, William Primack, George Retsch-Bogart, Desmond K. Runyan, Linmarie Sikich (also listed in Psychiatry), Leonard Stein, Alan D. Stiles, Richard W. Sutherland, Michael B. Tennison, Landrum S. Tucker Jr. (also listed in Psychiatry), Amy M. Ursano, Spencer G. Weig, Carlton Zdanski <br /><span style="font-weight: bold;">Pediatrics</span> - Wallace Brown, Julie Story Byerley, Alan W. Cross, Harvey J. Hamrick, James E. Kurz (also listed in Internal Medicine), Kimberly Kylstra, Jennifer L. Lail, Jacob A. Lohr, Kathy A. Merritt, Eliana M. Perrin, Kathleen Salter, Michael J. Steiner<br /><span style="font-weight: bold;">Physical Medicine and Rehabilitation </span>- Patricia C. Gregory, Michael Y. Lee<br /><span style="font-weight: bold;">Psychiatry</span> - L. Jarrett Barnhill (also listed in Pediatric Specialist), Robert A. Bashford (also listed in Pediatric Specialist), Alan Beeber, Julia L. Danek, James Cameron Garbutt, Bradley Gaynes, C. Thomas Gualtieri, David S. Janowsky, Julia S. Knerr, Maria C. La Via, Michael N. Macklin, Samantha E. Meltzer-Brody, Diana O. Perkins, Joseph Piven (also listed in Pediatric Specialist), David R. Rubinow, Linmarie Sikich (also listed in Pediatric Specialist), Landrum S. Tucker (also listed in Pediatric Specialist), Jr., Richard H. Weisler <br /><span style="font-weight: bold;">Pulmonary Medicine</span> - Richard C. Boucher, Michael Jon Cicale, James F. Donohue, David C. Henke (also listed in Critical Care Medicine), Michael Ray Knowles, Peadar Noone, Maria Patricia Rivera, James R. Yankaskas (also listed in Critical Care Medicine)<br /><span style="font-weight: bold;">Radiation Oncology</span> &ndash; Lawrence B. Marks, Julian G. Rosenman, Joel E. Tepper, Mahesh Kumar A. Varia<br /><span style="font-weight: bold;">Radiology</span> - Mauricio Castillio, Joseph K. T. Lee, Joseph M. Stavas<br /><span style="font-weight: bold;">Rheumatology</span> - MaryAnne Dooley, Nortin M. Hadler (also listed in Allergy and Immunology and Geriatric Medicine)<br /><span style="font-weight: bold;">Sleep Medicine</span> - Bradley Vaughn (also listed in Neurology)<br /><span style="font-weight: bold;">Surgery</span> - David A. Gerber, Anthony A. Meyer <br /><span style="font-weight: bold;">Surgical Oncology</span> - Benjamin F. Calvo, David W. Ollila<br /><span style="font-weight: bold;">Thoracic Surgery</span> - Thomas M. Egan, Richard H. Feins, Michael R. Mill (also listed in Pediatric Specialist)<br /><span style="font-weight: bold;">Urology</span> - Culley C. Carson III, Raj Pruthi, Eric Wallen <br /><br />Best Doctors, Inc. is based in Boston and provides highly specialized medical services to nearly 10 million people in over 30 countries. Best Doctors&rsquo; global database is updated continuously through a peer-review based evaluation of the medical profession, and includes 50,000 doctors worldwide named &ldquo;best,&rdquo; in over 40 specialties and 400 subspecialties of medicine. Best Doctors, Best Doctors in America and the star-in-cross logo are registered trademarks of Best Doctors, Inc. in the United States and other countries, and are used under license.</p>]]></content:encoded>
        <dc:publisher>No publisher</dc:publisher>
        <dc:creator>tom_hughes</dc:creator>
        <dc:rights></dc:rights>
        <dc:date>2009-11-19T15:04:53Z</dc:date>
        <dc:type>News Item</dc:type>
        </item>

    <item rdf:about="http://www.unchealthcare.org/site/newsroom/news/2009/November/mcallister">
    <title>Dedication of the UNC McAllister Heart Institute marks new era in heart research</title>
    <link>http://www.unchealthcare.org/site/newsroom/news/2009/November/mcallister</link>
    <description>Hugh “Chip” McAllister, M.D., an alumnus of the University of North Carolina at Chapel Hill School of Medicine, has made a three-part gift to establish the UNC McAllister Heart Institute.</description>   
    <content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<p><span style="font-weight: bold;">Media contact:</span> Stephanie Crayton, (919) 966-2860, <a href="mailto:scrayton@unch.unc.edu">scrayton@unch.unc.edu </a><br /><br />Embargoed until 2 p.m. Eastern time Wednesday, Nov. 4, 2009<br /><br />CHAPEL HILL &ndash; Hugh &ldquo;Chip&rdquo; McAllister, M.D., an alumnus of the <a href="http://med.unc.edu" target="_blank">University of North Carolina at Chapel Hill School of Medicine</a>, has made a three-part gift to establish the <a href="http://www.med.unc.edu/mhi" target="_blank">UNC McAllister Heart Institute</a>.<br /><br />An official ceremony celebrating the gift was held today (Nov. 4, 2009) at UNC. <br /><br />Cam Patterson, M.D., MBA, UNC&rsquo;s chief of cardiology and director of the Institute, says the McAllister gift, which formally changes the name of the Carolina Cardiovascular Biology Center, acknowledges the excellence in research and clinical care at UNC and will help the program expand its depth and breadth.<br /><br />&ldquo;Dr. McAllister&rsquo;s generosity will allow our faculty to stretch themselves, to push the edge of cardiovascular research. This is truly a transformative event for UNC and for our state,&rdquo; Patterson says.<br /><br />&ldquo;I want to support young scientists, the best in the country, in their work to understand cardiovascular disease,&rdquo; McAllister says.&nbsp;&ldquo;The mysteries of this disease will not be solved quickly, and so I want my gift to help further this research even after I'm gone.&rdquo;<br /><br />McAllister has given $7 million to date in outright gifts and other commitments.&nbsp; In addition, he has provided for the Institute in his will and made provisions for its support through his personal foundation, which will benefit the Institute for years afterward. <br /><br />Cardiovascular diseases are the most common causes of death and disability in the state of North Carolina and in the United States as a whole. The mission of the UNC McAllister Heart Institute is to advance the care of patients with diseases of the heart, blood and circulation by encouraging basic, preclinical, and applied research to unravel the causes of cardiovascular disease and to provide new tools for diagnosis and treatment of patients in North Carolina and beyond. <br /><br />Research programs in the Institute are organized within the center in the areas of cardiovascular physiology, cell biology and vascular development, thrombosis and hemostasis,&nbsp;clinical trials and translational research. There are 19 faculty laboratories, and a benefit of the McAllister gift will be the ability to attract even more world-class talent.<br /><br />McAllister earned his medical degree at UNC in 1966. From then until his retirement, he built a lengthy career as a highly respected and highly accomplished leader in cardiovascular pathology.<br /><br />He retired from active practice in 2000, after serving for 16 years as the founding chair of the <a href="http://www.texasheart.org/Research/cvpathresearch.cfm" target="_blank">Department of Cardiovascular Pathology</a> at the <a href="http://www.texasheart.org/index.cfm" target="_blank">Texas Heart Institute</a> at St. Luke&rsquo;s Episcopal Hospital in Houston. This followed his equally distinguished career in the U.S. Army Medical Corps, where he served for 13 years as chair of the Department of Cardiovascular Pathology at the Armed Forces Institute of Pathology in Washington, D.C., from 1971 to 1984.<br /><br />McAllister&rsquo;s roots at the UNC School of Medicine run deep. His father, Hugh A. McAllister Sr., M.D., earned his Certificate of Medicine at UNC in 1935. McAllister Sr. practiced obstetrics and gynecology in his hometown of Lumberton, N.C. for four decades before his death in 1978. He was honored with the School of Medicine&rsquo;s Distinguished Service Award in 1963, while his son was working towards his medical degree at UNC.<br /><br />Chip McAllister&rsquo;s professional accomplishments are too numerous to provide a comprehensive listing here. Some of the more noteworthy items include:</p><ul><li>An impressive record of scholarly publications, including four textbooks and 39 chapters in other medical books</li><li>An exhaustive atlas he compiled with co-author Dr. John Fenoglio in 1978, titled Tumors of the Cardiovascular System, which has been described as &ldquo;a recognized classic in medical literature&rdquo; and &ldquo;a work of enduring usefulness&rdquo;</li><li>The Legion of Merit of the United States of America in 1984 and the Distinguished Achievement Award from the Society for Cardiovascular Pathology in 2001 and many, many others.</li></ul><p><br />McAllister is the current president of the UNC Medical Alumni Association, a member of the UNC Board of Visitors and an executive committee member of the Medical Foundation of North Carolina.<br /><br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>]]></content:encoded>
        <dc:publisher>No publisher</dc:publisher>
        <dc:creator>tom_hughes</dc:creator>
        <dc:rights></dc:rights>
        <dc:date>2009-11-03T15:14:34Z</dc:date>
        <dc:type>News Item</dc:type>
        </item>

    <item rdf:about="http://www.unchealthcare.org/site/newsroom/news/2009/November/roth">
    <title>Study points to new uses, unexpected side effects of already-existing drugs</title>
    <link>http://www.unchealthcare.org/site/newsroom/news/2009/November/roth</link>
    <description>Scientists at the University of North Carolina at Chapel Hill School of Medicine and the University of California, San Francisco have developed and experimentally tested a technique to predict new target diseases for existing drugs.
</description>   
    <content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<p><span style="font-weight: bold;">Media contact:</span> Les Lang, (919) 966-9366, <a href="mailto:llang@unch.unc.edu">llang@unch.unc.edu</a><br /><br />Wednesday, Nov. 4, 2009<br /><br />CHAPEL HILL &ndash; Scientists at the University of North Carolina at Chapel Hill School of Medicine and the University of California, San Francisco have developed and experimentally tested a technique to predict new target diseases for existing drugs. <br /><br />The researchers developed a computational method that compares how similar the structures of all known drugs are to the naturally occurring binding partners -- known as ligands -- of disease targets within the cell. In a study published this week in Nature, the scientists showed that the method predicts potential new uses as well as unexpected side effects of approved drugs.<br /><br />&nbsp;&ldquo;This approach uncovered interactions between drugs and targets that we never could have predicted simply by looking at the chemical structures,&rdquo; said senior study author Bryan Roth, M.D., Ph.D., professor of pharmacology and director of the National Institute of Mental Health Psychoactive Drug Screening Program at UNC. &ldquo;We may now have a way to predict what side effects are likely to occur from treatment before we even put a drug into clinical testing.&rdquo;&nbsp; Roth is also a member of the UNC Lineberger Comprehensive Cancer Center.<br /><br />Many of the most successful drugs on the market today are being prescribed for ailments that are quite different from the ones they were originally designed to treat. Viagra, for instance, was once intended for coronary heart disease but now is used to combat erectile dysfunction. The discovery of surprising uses of developed drugs can sometimes be the result of serendipity, as unforeseen side effects emerge from clinical trials. In the past, researchers have tried to predict drug interactions by looking for chemical similarities among the possible targets of pharmaceutical compounds. <br /><br />However, some drug targets which look very similar to one another bind very different ligands, and some targets that don't have any obvious similarity bind similar ligands, says Brian Shoichet, Ph.D., co-senior study author and professor of pharmaceutical chemistry at UCSF. &ldquo;So if instead we were to organize targets by the ligands they recognize, it could reveal different patterns than traditional approaches, and illuminate new opportunities for drugs to bind to unexpected targets.&rdquo;<br /><br />A team of researchers led by Roth and Shoichet did just that, comparing the structures of 3,365 FDA-approved and investigational drugs against the structures of hundreds of targets, defining each target by its ligands. They then honed in on thirty of the strongest predictions, validating the actual physical interactions between the drugs and targets in wet laboratory experiments. <br /><br />In one of their follow-up experiments, the scientists investigated the molecular targets of the hallucinogenic substance dimethyltrytamine (DMT), which had previously been postulated to act through a site known as the sigma-1 receptor. Using the computational approach, Roth and colleagues found that DMT had a high affinity for serotonin receptors, including the binding site for LSD, another hallucinogen. <br /><br />They also showed that the substance is hallucinogenic in normal mouse models but not in ones lacking the serotonin receptor. Roth says the power of their approach is it can be used to uncover the real targets of pharmaceutical compounds quickly and efficiently, and will probably lead to a greater understanding of the many molecular targets of each drug.<br /><br />&ldquo;Drugs are not as selective as we once thought,&rdquo; said Roth, who is also a professor in the School of Pharmacy&rsquo;s medicinal chemistry and natural products division. &ldquo;It turns out that the most non-selective drugs are frequently the most effective for complex diseases. Rather than &lsquo;magic bullets,&rsquo; we need to come up with &lsquo;magic shotguns&rsquo; that hit more than one molecular target at a time. We could use this computational approach to identify the drugs that hit the right targets and miss the wrong ones.&rdquo;<br /><br />Study co-authors from UNC include Vincent Setola, research associate professor; Atheir Abbas, former graduate student; Sandra J. Hufeisen, senior research assistant; Niels H. Jensen, research associate; Michael B. Kuijer, research technician; Roberto C. Matos, research technician; Thuy B. Tran, research technician; Ryan Whaley, research technician; and Richard A. Glennon.&nbsp; The paper&rsquo;s first author is Dr. Michael Keiser, from the UCSF side of the collaboration.&nbsp; Also from UCSF were Drs. John Irwin, Christian Laggner and Jerome Hert, and PharmDs Kelan Thomas and Douglas Edwards. <br /><br />Funding for the studies at UNC and at UCSF came from the National Institutes of Health.</p>]]></content:encoded>
        <dc:publisher>No publisher</dc:publisher>
        <dc:creator>tom_hughes</dc:creator>
        <dc:rights></dc:rights>
        <dc:date>2009-11-04T14:18:28Z</dc:date>
        <dc:type>News Item</dc:type>
        </item>

    <item rdf:about="http://www.unchealthcare.org/site/newsroom/news/2009/October/itouch">
    <title>No longer lost in translation: Interpreters replace pagers with iPod touch</title>
    <link>http://www.unchealthcare.org/site/newsroom/news/2009/October/itouch</link>
    <description>At UNC Hospitals, the Interpreter Services department has dumped both pagers and cell phones in favor of a device they find to be much more effective in meeting their needs: the Apple iPod touch.</description>   
    <content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<p><span style="font-weight: bold;">Media contact:</span> Tom Hughes, (919) 966-6047, <a href="mailto:tahughes@med.unc.edu">tahughes@med.unc.edu </a><br />
<br />
Thursday, Oct. 29, 2009<br />
<br />
CHAPEL HILL &ndash; Pagers are ubiquitous in the hospital setting. They are so familiar and common, in fact, that they are even used for comic effect on medically themed TV dramas such as <a href="http://www.housemd-guide.com/season4/408know.php" target="_blank">&ldquo;House M.D.&rdquo; </a><br />
<br />
But at UNC Hospitals, the Interpreter Services department has dumped both pagers and cell phones in favor of a technology they find to be much more effective in meeting their needs: the <a target="_blank" href="http://www.apple.com/ipodtouch/">Apple iPod touch</a>.</p>


<p><embed height="260" width="320" align="right" type="application/x-shockwave-flash" src="http://www.unchealthcarevideos.org/jwplayer.swf" style="" id="ply" name="ply" bgcolor="#FFFFFF" quality="high" allowfullscreen="true" allowscriptaccess="always" flashvars="file=http://www.unchealthcarevideos.org/News/2009/10/itouch.mov&amp;image=http://www.unchealthcare.org/site/newsroom/images/itouch-preview.jpg"></embed></p>

<p>Juan Reyes-Alonso, who started working as an interpreter at UNC Hospitals in 2003, explains what it was like for the hospitals&rsquo; 26 interpreters to work with the pager system that was in place back then.<br />
<br />
&ldquo;All of us carried pagers, and there was just one pager phone number for all of us. So, when a doctor requested an interpreter, all of our pagers would go off at the same time. And all of us who were free at the time would call the doctor back, so the doctor might get calls from 10 different interpreters all at once. It was a mess!&rdquo; said Reyes-Alonso, UNC Hospitals&rsquo; lead interpreter.<br />
<br />
About five years ago, the interpreters dropped the pager system and started using cell phones in conjunction with a Web-based dispatch management service called <a href="http://www.servicehub.info/" target="_blank">ServiceHub</a>. The service was originally designed to meet the needs of the transportation and field service industries. UNC Hospitals was ServiceHub&rsquo;s first hospital client, said Hans Wynholds, chairman of the Cupertino, Calif.-based company.</p>
<p>Shane Rogers, director of Interpreter Services at UNC Hospitals, said the ServiceHub system was a big improvement over the pager system. <br />
<br />
&ldquo;The ServiceHub system gave us many advantages that we didn&rsquo;t have before,&rdquo; Rogers said. &ldquo;For example, it gave people requesting interpreters a Web page for submitting their requests, and they could see whether or not an interpreter had been assigned to handle their request, and if so, which one.&rdquo;<br />
<br />
&ldquo;But the cell phones we were using didn&rsquo;t work as well as we had hoped. In some parts of the hospital cell phones just can&rsquo;t get a signal. And sometimes the cell phone service would go down, and then we had to rely on the phone company to get it up and running again.&rdquo;<br />
<br />
A possible solution to that problem presented itself about a year ago, when UNC Hospitals began installing a WiFi system throughout the medical center. &ldquo;Once the hospitals&rsquo; own wireless system was in place, we realized this could be an opportunity for us to use wireless handheld devices instead of pagers or cell phones,&rdquo; Rogers said.<br />
<br />
So, Rogers asked ServiceHub if this was possible. ServiceHub then re-wrote the mobile portion of their customized software for UNC Hospitals that enabled the interpreters to access the ServiceHub system from handheld wireless devices.</p>
<p>&nbsp;</p>
<table border="0" align="right">
    <tbody>
        <tr>
            <td>&nbsp;</td>
            <td>&nbsp;<a href="../../../images/servicehub5.jpg"><img height="" width="" alt="ServiceHub screen shot" src="../../../images/servicehub5.jpg" /></a></td>
        </tr>
        <tr>
            <td>&nbsp;</td>
            <td>
            <em>An iPod touch screen shot from the ServiceHub system. <br />
            (The names and data shown here are fictional.)<br />
            </em>
            </td>
        </tr>
    </tbody>
</table>
<p>At that point, Reyes-Alonso tested the system with several wireless devices, including the iPod Touch and Web-enabled cell phones. Of the half dozen or so devices he tested, he found the iPod Touch to be the easiest to use and the most effective, Reyes-Alonso said.</p>
<p>All 26 interpreters began carrying an iPod Touch in early September 2009. With the iPod Touch, the interpreters are always connected, no matter where they might be inside UNC Hospitals. When an interpreter responds to a request, all the other interpreters can see that response almost instantly, so the requester doesn&rsquo;t get calls from 10 interpreters all at once. In addition, many tasks that used to require a computer &ndash; such as consulting a bilingual medical dictionary &ndash; can now be done through the iPod Touch.<br />
<br />
&ldquo;The iPod Touch has greatly reduced a lot of the frustrations we used to have with our pagers and our cell phones,&rdquo; Reyes-Alonso said. &ldquo;I love it.&rdquo;</p>
<p>Rogers cites additional advantages.<br />
<br />
&ldquo;Now that we&rsquo;re using the hospitals&rsquo; own wireless system, if the system goes down, then we&rsquo;ll be dealing with our own people to get it back up, instead of having to call the phone company and wait for them to take care of it.&rdquo; Plus, Rogers said, the monthly cost to his department to lease their iPod Touches from ServiceHub is about half what it cost for the same number of cell phones.<br />
<br />
Wynholds says UNC Hospitals was the first of its hospital clients to fully implement the mobile version of its system. Several other hospitals are now thinking about following UNC Hospitals&rsquo; example, he said.<br />
<br />
&ldquo;UNC has really embraced the technology, and they have worked hard to help us understand how to make it work effectively in the hospital environment,&rdquo; he said.<br />
<br />
&ldquo;We&rsquo;ve learned a lot in working with UNC over the years, and we&rsquo;ve pretty much allowed the product to evolve in line with their specifications.&rdquo;</p>]]></content:encoded>
        <dc:publisher>No publisher</dc:publisher>
        <dc:creator>tom_hughes</dc:creator>
        <dc:rights></dc:rights>
        <dc:date>2009-10-29T20:44:17Z</dc:date>
        <dc:type>News Item</dc:type>
        </item>

    <item rdf:about="http://www.unchealthcare.org/site/newsroom/news/2009/October/bcrf">
    <title>Breast Cancer Research Foundation funds four at UNC Lineberger</title>
    <link>http://www.unchealthcare.org/site/newsroom/news/2009/October/bcrf</link>
    <description>Four faculty members from UNC Lineberger Comprehensive Cancer Center have been awarded yearlong grants from the Breast Cancer Research Foundation (BCRF).</description>   
    <content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<p><span style="font-weight: bold;">Contact:</span> Ellen de Graffenreid, (919) 962-3405, <a href="mailto:edegraff@med.unc.edu">edegraff@med.unc.edu</a><br /><br />CHAPEL HILL, NC &ndash; Four faculty members from <a href="http://cancer.med.unc.edu/" target="_blank">UNC Lineberger Comprehensive Cancer Center</a> have been awarded yearlong grants from the <a href="http://www.bcrfcure.org/" target="_blank">Breast Cancer Research Foundation (BCRF)</a>.<br /><br /><a href="http://www.unclineberger.org/research/faculty/displayMember.asp?ID=25" target="_blank">Dr. Lisa Carey</a>, medical director of the UNC Breast Center and associate professor of medicine; <a href="http://cancer.unc.edu/research/faculty/displayMember.asp?ID=50" target="_blank">Dr. H. Shelton Earp</a>, Lineberger professor and director of the UNC Lineberger Comprehensive Cancer Center; <a href="http://cancer.unc.edu/research/faculty/displayMember.asp?ID=642" target="_blank">Dr. Hyman Muss</a>, director of geriatric oncology at UNC Lineberger and professor of medicine and <a href="http://cancer.unc.edu/research/faculty/displayMember.asp?ID=244">Dr. Charles Perou</a>, associate professor of genetics and pathology. Each received a one-year grant designed to further promising research in the field of breast cancer.&nbsp;&nbsp; <br /><br />&ldquo;We are proud to be one of only a handful of university cancer centers to receive four grants from BCRF this year.&nbsp; The foundation and the generous people and organizations who support their research programs expect the highest degree of scientific merit and we are pleased to be well-represented in this elite group,&rdquo; said Earp.<br /><br />BCRF is supporting a clinical trial led by Dr. Carey, designed to understand which women benefit most and are harmed the least by chemotherapy.&nbsp; Carey and her colleagues are collecting genetic material from 1,000 breast cancer patients and 1,000 healthy women of similar age, race, and ethnicity before breast cancer patients are treated with chemotherapy, allowing researchers to directly measure responsiveness of their breast cancer to chemotherapy that is given.&nbsp; By comparing the genetic profiles in those patients who respond to chemotherapy with those who do not, the team can validate which genetic mutations are associated with differences in treatment outcomes.<br /><br />Dr. Earp&rsquo;s team will continue a three-part research program focused on developing a new and Improved Anti-HER2 Breast Cancer Vaccine; understanding the genetic determinants of breast cancer&rsquo;s development and response to therapy; and examining the EGF Receptor family in breast cancer and the role of HER4.&nbsp; <br /><br />The first project performed with Dr. Jon Serody is a therapeutic cancer vaccine clinical trial that combines two drugs with the vaccine in the treatment of women with high HER2-expressing metastatic breast cancer.&nbsp; The second project has worked with more than 1,000 women to obtain DNA samples as well as epidemiologic, clinical, therapeutic and outcome data so that researchers can better understand how complex genetic inheritance influences a woman&rsquo;s predisposition to breast cancer.&nbsp; Finally, the researchers are studying another member of the EGF/HER2 receptor family, HER4.&nbsp; One variant of HER4 slows breast cancer cell growth, while the other actually stimulates growth.&nbsp; The team hopes to unravel the mechanisms by which those two variants, which differ by only one percent of the gene&rsquo;s length, have opposite effects on breast cancer cell growth.<br /><br />Dr. Muss&rsquo; new project focuses on patients aged 65 and older, assessing the costs and benefits of adjuvant chemotherapy.&nbsp; While this therapy has been shown to improve survival in older women with breast cancer, side effects may interfere with the quality of life and daily function.&nbsp; In collaboration with UNC Lineberger colleague Dr. Ned Sharpless, Muss&rsquo; team is seeking to understand the effect of adjuvant chemotherapy on a biomarker of aging called p16INKa.&nbsp; They will also measure the biomarker in patients treated only with surgery and those treated with adjuvant endocrine therapy to determine if the increased expression of this biomarker in some older patients is associated with their susceptibility to the age-promoting effects and associated toxicities of chemotherapy.<br /><br />Dr. Perou&rsquo;s team is focused on two subtypes of breast cancer that are associated with poor clinical outcomes, &ldquo;Luminal B&rdquo; and &ldquo;Claudin-low.&rdquo;&nbsp; The team is focused on identifying how genetic alterations cause these tumors and determining the role of stem cells in their biology.&nbsp; Using the genomic data for these tumor types and key clinical data, Perou&rsquo;s team is building a predictive mathematical model for breast cancer patient outcomes that could assist doctors in making therapeutic decisions.<br />About BCRF<br /><br />The Breast Cancer Research Foundation is an independent 501 (c) (3) not-for-profit organization whose mission is to achieve prevention and a cure for breast cancer in our lifetime by providing critical funding for innovative clinical and translational research at leading medical centers worldwide, and increasing public awareness about good breast health. More information is available at www.bcrfcure.org.</p>]]></content:encoded>
        <dc:publisher>No publisher</dc:publisher>
        <dc:creator>tom_hughes</dc:creator>
        <dc:rights></dc:rights>
        <dc:date>2009-10-26T20:24:23Z</dc:date>
        <dc:type>News Item</dc:type>
        </item>

    <item rdf:about="http://www.unchealthcare.org/site/newsroom/news/2009/October/goldberg">
    <title>Clinical trial promotes new standards for colorectal cancer treatment</title>
    <link>http://www.unchealthcare.org/site/newsroom/news/2009/October/goldberg</link>
    <description>In a review article published this month in The Oncologist, UNC’s Dr. Richard M. Goldberg and a team of colleagues catalogue how the data collected in a single large comparative clinical trial testing combination chemotherapy for metastatic colorectal cancer has been used not only to benefit the patients that enrolled but also patients who subsequently developed the disease.
</description>   
    <content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<p><span style="font-weight: bold;">Contact:</span>&nbsp; Ellen de Graffenreid, 919-962-3405,  <a href="mailto:edegraff@med.unc.edu">edegraff@med.unc.edu</a><br /><br />Monday, October 26, 2009<br /><br />CHAPEL HILL, NC &ndash; In a review article published this month in The Oncologist, UNC&rsquo;s Dr. Richard M. Goldberg and a team of colleagues&nbsp;catalogue how the data collected in a single large comparative clinical trial testing combination&nbsp;chemotherapy for metastatic colorectal cancer has been used not only to benefit the patients that enrolled but also&nbsp;patients who subsequently&nbsp;developed the disease. <br /><br />It has also helped to refine the&nbsp;clinical trials process&nbsp;and move forward the potential for individualized therapy for patients. These benefits&nbsp;of this collaboration between patients, physicians across the U.S. and Canada, the National Cancer Institutes of the U.S. and Canada, and two pharmaceutical companies (Pharmacia and sanofi-aventis) are being still being realized&nbsp;five years after the original trial concluded.<br />&nbsp;<br />Not only did the Phase III trial, which ran from 1997-2004, prove that combination chemotherapies adding new drugs to the standard treatment in use for 50 years are effective in treating metastatic colorectal cancer, but it also provided data for more than&nbsp;25 additional scientific papers.&nbsp; This ongoing research&nbsp;has helped to improve&nbsp;the prognosis and change the standard of care for patients with this diagnosis.<br />&nbsp;<br />&ldquo;The history of this study shows how patients&rsquo; decisions to enroll in clinical trials can benefit thousands of others, even years down the road,&rdquo; said Goldberg, who is Physician-in-Chief of the N.C. Cancer Hospital and Associate Director for Clinical Research at UNC Lineberger Comprehensive Cancer Center.<br />&nbsp;<br />&ldquo;These individuals have helped doctors and scientists change the way we treat metastatic colorectal cancer and simplify&nbsp;the way we&nbsp;run clinical trials in cancer patients.&rdquo; Based on the trial the US Food and Drug Administration&nbsp;approved&nbsp;a new agent, oxaliplatin,&nbsp;administered with 5-fluorouracil for the indication&nbsp;&quot;treatment of previously untreated patients with colorectal cancer that had spread to other organs&quot; in&nbsp;2004.<br />&nbsp;<br />As one of the first clinical trials to monitor chemotherapy toxicity in real-time, the study allowed researchers to quickly eliminate drug combinations that were more likely to result in negative outcomes for patients.&nbsp; Over the course of the study, as the field of pharmacogenetics evolved, researchers were able to use the individual patients' DNA collected with a simple blood test to better pinpoint which&nbsp;were most likely to have severe side effects.&nbsp; The DNA analysis also helps doctors determine which patients derive greater benefits from a particular drug and adjust their chemotherapy&nbsp;to minimize risk, while maximizing the chances that their cancer would respond to therapy.<br />&nbsp;<br />&ldquo;Over time, the fact that this study collected DNA and plasma with patient permission has been important to our ability to make significant progress in understanding how patients&rsquo; genetic profiles interact with anti-cancer drugs,&rdquo; said Goldberg.<br />&nbsp;<br />Data from the study was also used to examine how patients did with a combination of surgery and drug therapy, to study how the combination drug therapy worked in patients with different risk profiles based on the type and progression of their cancer, and to assess the economic cost-benefit of combination therapies.<br />&nbsp;<br />&quot;The original data collected has also been combined with data from other clinical trials to examine overall survival rates and to explore&nbsp;differences in outcomes based on patient age and symptom profiles so that we could understand the risks and benefits when we treat older and sicker patients with the&nbsp;more intensive&nbsp;treatments&quot; Goldberg said. &quot;The data was also used to simplify how we follow tumor measurements and side effect profiles in clinical trials speeding the pace and reducing the cost of research.&quot;<br />&nbsp;<br />&ldquo;The history of this study demonstrates how sharing data among groups of scientists and doctors and asking questions that span scientific disciplines can help us make progress that is meaningful for patients over the relatively short time frame of approximately a decade,&rdquo; he added.<br />&nbsp;<br />Other investigators on the review study were Hanna Sanoff, MD, clinical assistant professor of medicine and Howard McLeod, PharmD, professor of pharmacy and UNC Lineberger member, Daniel J. Sargent, PhD, Erin Green and Jan Buckner, MD from the Mayo School of Medicine in Rochester, Minnesota, and Roscoe Morton, MD from the Iowa Oncology Research Association CCOP.<br />&nbsp;<br />The original clinical trial was a partnership between the enrolled patients, the National Cancer Institutes of the US and Canada, NCI sponsored cooperative groups, industry, and investigators at academic centers, Community Clinical Oncology Programs and private practices.&nbsp; The review study was supported by the North Central Cancer Treatment Group (NCCTG) and NCCTG Biospecimen Resource, sanofi-aventis and Pharmacia.<br /><br />&nbsp;<br />&nbsp;</p>]]></content:encoded>
        <dc:publisher>No publisher</dc:publisher>
        <dc:creator>tom_hughes</dc:creator>
        <dc:rights></dc:rights>
        <dc:date>2009-10-27T13:43:38Z</dc:date>
        <dc:type>News Item</dc:type>
        </item>

    <item rdf:about="http://www.unchealthcare.org/site/newsroom/news/2009/October/dominski">
    <title>Messenger RNA with FLASH</title>
    <link>http://www.unchealthcare.org/site/newsroom/news/2009/October/dominski</link>
    <description>A study from the University of North Carolina at Chapel Hill has identified a key player in a molecular process essential for DNA replication within cells.</description>   
    <content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<p><span style="font-weight: bold">Media contact:</span> Les Lang (919) 966-9366, <a target="_blank" href="mailto:llang@med.unc.edu">llang@med.unc.edu</a><br /><br />Thursday, Oct. 22, 2009</p><p>CHAPEL HILL -- A study from the University of North Carolina at Chapel Hill has identified a key player in a molecular process essential for DNA replication within cells. <br /><br />The new findings highlight a protein called FLASH, already shown to play a role in initiating apoptosis, or programmed cell death.&nbsp; Apoptosis is a normal biochemical response that occurs when a cell is damaged beyond repair after viral infection or accumulation of mutations that could lead to uncontrolled cellular proliferation, or cancer.&nbsp; Apoptosis is also crucial to the developing embryo through selective cell death, which allows proper differentiation of physical structures, such as fingers and toes.<br /><br />According to senior study author Zbigniew Dominski, Ph.D., associate professor of <a target="_blank" href="http://www.med.unc.edu/biochem">biochemistry and biophysics</a> at UNC, the new study demonstrates that FLASH is also required for the proper synthesis of histone messenger RNA, which gives rise to histone proteins. <br /><br />Histones are the chief protein components of chromatin and act as a scaffold allowing packaging of DNA into a condensed form that fits inside the nucleus of a cell. As the DNA interacts with histones and with metabolic signals from within the cell, these proteins help regulate gene expression.<br /><br />&ldquo;Our study suggests for the first time that a potential link exists between the processes of histone messenger RNA formation and apoptosis,&rdquo; Dominski said. &ldquo;FLASH is crucial for the production of histone messenger RNA, without which the cell can&rsquo;t make the histone proteins around which DNA is packaged.&rdquo;<br /><br />The research is described in the Oct. 23, 2009 issue of the journal <a target="_blank" href="http://www.sciencedirect.com/science/journal/10972765">Molecular Cell</a>.<br /><br />For the study, Dominski adapted a laboratory system that reproduces in the test tube what normally occurs in the cell when FLASH participates in the biochemical cleavage event that results in mature histone messenger RNA. This enabled his team to explore what might occur when FLASH was added or removed. <br /><br />&ldquo;We could then figure out exactly what portion of FLASH would restore the protein&rsquo;s function in generating histone mRNAs and remarkably, only the first 100 or so amino acids are required.&nbsp; The remaining 2,000 amino acids of this large protein likely control other processes in the cell, including apoptosis and DNA replication,&rdquo; he explained.<br /><br />Co-author William F. Marzluff, Ph.D., is distinguished professor of biochemistry and biophysics and executive associate dean for basic research in the <a target="_blank" href="http://med.unc.edu.">UNC School of Medicine</a>. He noted that FLASH is the first component found in this protein complex &ldquo;that integrates or initiates many cellular functions &ndash; DNA replication, apoptosis, histone production.&nbsp; Having this small piece of the puzzle makes it a lot easier to identify others.&rdquo;&nbsp; <br /><br />Other UNC coauthors include Xiao-cui Yang, laboratory technician, and Yan Yan, undergraduate student, both from the D<a target="_blank" href="http://www.med.unc.edu/biochem">epartment of Biochemistry and Biophysics</a> and the <a target="_blank" href="http://www.med.unc.edu/pmbb/">UNC Program in Molecular Biology and Biotechnology</a> and Brandon D. Burch, graduate student in in genetics and molecular biology. <br /><br />Funding for the study came from the <a target="_blank" href="http://www.nigms.nih.gov/">National Institute of General and Medical Sciences</a>, a component of the <a target="_blank" href="http://www.nih.gov/">National Institutes of Health</a>.<br /><br /><br /><br />&nbsp;</p>]]></content:encoded>
        <dc:publisher>No publisher</dc:publisher>
        <dc:creator>tom_hughes</dc:creator>
        <dc:rights></dc:rights>
        <dc:date>2009-10-26T16:20:05Z</dc:date>
        <dc:type>News Item</dc:type>
        </item>

    <item rdf:about="http://www.unchealthcare.org/site/newsroom/news/2009/October/fhd6">
    <title>Family House Diaries: Going Forward in All New Skin </title>
    <link>http://www.unchealthcare.org/site/newsroom/news/2009/October/fhd6</link>
    <description>20-year-old Caitlin Hughes of Charlotte lost 90 percent of her skin after suffering a severe reaction to antibiotics prescribed for acne. This is the story of her remarkable recovery.</description>   
    <content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<p><span style="font-weight: bold;">Media contacts: </span>Tom Hughes, (919) 966-6047, <a href="mailto:tahughes@unch.unc.edu">tahughes@unch.unc.edu</a>, or Clinton Colmenares, (919) 966-8757, <a href="mailto:ccolmena@unch.unc.edu">ccolmena@unch.unc.edu </a><span style="font-style: italic;"><br /><br />Written by Elizabeth Swaringen for the UNC Medical Center News Office</span><br /><br />Wednesday, Oct. 21, 2009<br /><br />CHAPEL HILL, N.C. &ndash; Finally, 20-year-old Caitlin Hughes&rsquo; acne is gone, but getting her new skin nearly killed her.&nbsp; <br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <br />A reaction to an antibiotic of last resort &ndash; prescribed to rid the University of North Carolina junior from Charlotte of life-long acne &ndash; caused Hughes to contract Stevens-Johnson Syndrome (SJS), a rare disorder in which skin and mucous membranes react severely to medications or infection.&nbsp; <br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <br />But Hughes&rsquo; diagnosis was even more worrisome &ndash; a severe form of SJS called Toxic Epidermal Necrolysis (TEN) &ndash; meaning that at least 30 percent of her skin was blistered, dying and shedding.&nbsp; Her skin sloughing progressed rapidly to ultimately involve more than 90 percent of her entire body.<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <br />The medical emergency landed Hughes in the <a href="http://www.med.unc.edu/burn" target="_blank">N.C. Jaycee Burn Center</a> at UNC Hospitals.&nbsp; About 50 of the nearly 800 patients admitted to the burn center annually are SJS/ TEN patients because their damaged skin and membranes mimic that of burn patients. <br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <br />&quot;This is a mysteriously devastating disease,&rdquo; said <a href="http://findadoc.unchealthcare.org/directory/profile.asp?dbase=main&amp;setsize=10&amp;last=cairns&amp;first=bruce&amp;pict_id=0001772" target="_blank">Bruce A. Cairns, M.D.</a>, medical director of the N.C. Jaycee Burn Center. &ldquo;Patients can present with a rash and within 24 hours nearly all of their skin can slough off. And sloughing can affect other mucosal surfaces, including the mouth, the respiratory tract, the gastrointestinal system and the eyes.&rdquo;&nbsp; <br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <br />Fortunately, TEN is relatively rare &ndash; about three in a million &ndash; but can develop as a severe reaction to a number of medications. In the most severe cases, the mortality rate from SJS/TEN can be as high as 30-50 percent. <br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <br />The principal treatment is essentially supportive, Cairns said, meaning that, &ldquo;We have to let the disease run its course and help support the patient during that crucial time. Sometimes it takes weeks, but many times it takes months. In Caitlin&rsquo;s case, once she began to improve, she healed rapidly, and she was out of the hospital in weeks.&rdquo;<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <br />Caitlin believes her near-record recovery speaks to the &ldquo;developed expertise and innate compassion&rdquo; of her health care team. &ldquo;I&rsquo;ve never seen people smiling more when they should be crying,&rdquo; she said. <br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <br />Caitlin had planned to spend the fall term in Chapel Hill pursuing her psychology major and continuing a research project about non-suicidal self-injury among girls.&nbsp; That after a six-week, eye-opening summer study abroad in genocide-ridden Rwanda. <br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <br />Physically, she was in the best shape of her life, returning from Africa to work out regularly at the YMCA. She delayed the new acne regimen until after Rwanda because she thought the vaccinations required for life abroad might interfere with its effectiveness.&nbsp; It was a decision that saved her life. <br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <br />&ldquo;I would have been on the plane when the rash began, and I would have died because the rash and blisters moved with such speed,&rdquo; Caitlin said.&nbsp;&nbsp;&nbsp; <br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <br />Mid-August back in Charlotte, the rash started as three dots on Caitlin&rsquo;s right wrist, spread to her stomach, into her mouth, down her throat and into her esophagus. Her vocal chords were damaged.&nbsp; She was hospitalized on Aug. 16, had a breathing tube placed in her throat to keep her airway open and was placed in a medically induced coma so that she was unaware of the pain of losing nearly all her skin.&nbsp; <br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <br />Her head was shaved to manage the blisters on her scalp.&nbsp; Within three days of having 30 percent abrasions on both corneas, her blistered eyes healed, her sight returned and her depth perception is improving. Only her hands and feet escaped the shedding skin.<br /><br />&ldquo;The fact that her hands and feet were spared gave her a head start on rehabilitation because she didn&rsquo;t have to relearn how to use them,&rdquo; said Pam Hughes, Caitlin&rsquo;s mother.&nbsp; &ldquo;We have seen so many miracles with her, and God&rsquo;s hand at work in so many ways.&rdquo; <br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <br />While Caitlin was hospitalized, her parents stayed at the <a href="http://www.secufamilyhouse.org/" target="_blank">SECU (State Employees&rsquo; Credit Union) Family House</a>, a 40-bedroom hospital hospitality house minutes from UNC Hospitals that provides comfortable, convenient and affordable housing for adult patients undergoing treatment for critical illness and trauma and their family member caregivers.&nbsp; <br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <br />&ldquo;SECU Family House offered an excellent respite from being at the hospital all day,&rdquo; Pam said.&nbsp; &ldquo;Despite the circumstances, I am glad I was able to be with Caitlin almost non-stop for a month.&nbsp; We cannot say enough good things about the house and staff, most of whom are volunteers.&rdquo;&nbsp; <br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <br />Caitlin joined her mother at SECU Family House on Sept. 16 for three weeks of outpatient rehabilitation before returning to Charlotte on Oct. 9.&nbsp; Earlier that week, she was strong enough to participate in a Fellowship of Christian Athletes outing that involved a rigorous scavenger hunt.&nbsp; Caitlin&rsquo;s team earned second place and best group picture honors.&nbsp;&nbsp;&nbsp; <br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <br />&ldquo;She&rsquo;s always been my independent child, the fighter,&rdquo; Pam said.&nbsp; &ldquo;I now know that was God preparing her for overcoming this illness.&nbsp; She was in God&rsquo;s hands, she got excellent medical care, and she had a strong will to survive.&nbsp; Her world is big, and she will be off to tackle it.&rdquo; <br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <br />Caitlin plans to be back in Chapel Hill as a student when the spring term begins in January.&nbsp; And she plans to stop by the Burn Center to see her new friends there and talk with the families of SJS patients to help ease their journey.<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <br />&ldquo;Caitlin&rsquo;s recovery is the kind of result we would love to have every time,&rdquo; Cairns said, adding that Caitlin will continue to be followed closely for any potential long-term problems related to TEN.<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <br />&ldquo;I left the hospital with a shaved head, a tracheotomy scar, a bum shoulder from some nerve damage, and all new skin which is clear and smooth,&rdquo; Caitlin said. &ldquo;I survived and I&rsquo;ve got lots to accomplish. And when I&rsquo;m 40 years old, my skin will just be 20!&rdquo;</p>]]></content:encoded>
        <dc:publisher>No publisher</dc:publisher>
        <dc:creator>tom_hughes</dc:creator>
        <dc:rights></dc:rights>
        <dc:date>2009-10-21T13:16:41Z</dc:date>
        <dc:type>News Item</dc:type>
        </item>




</rdf:RDF>
